Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will post its quarterly earnings results after the market closes on Thursday, November 2nd. Analysts expect Atara Biotherapeutics to post earnings of ($0.97) per share for the quarter.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.05). On average, analysts expect Atara Biotherapeutics to post $-3.99 EPS for the current fiscal year and $-4.6 EPS for the next fiscal year.
Atara Biotherapeutics, Inc. (ATRA) opened at 14.15 on Tuesday. The company’s 50 day moving average price is $15.37 and its 200-day moving average price is $15.02. Atara Biotherapeutics, Inc. has a one year low of $11.80 and a one year high of $23.00. The stock’s market capitalization is $432.41 million.
COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics, Inc. (ATRA) to Release Earnings on Thursday” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2017/10/31/atara-biotherapeutics-inc-atra-to-release-earnings-on-thursday.html.
A number of equities analysts recently commented on ATRA shares. ValuEngine lowered Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Canaccord Genuity set a $47.00 price target on Atara Biotherapeutics and gave the company a “buy” rating in a research note on Monday, August 7th. BidaskClub lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 price target for the company in a research note on Tuesday, August 22nd. Finally, Jefferies Group LLC reissued a “buy” rating and set a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, August 31st. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $24.40.
In other news, EVP Christopher Haqq sold 7,604 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $14.75, for a total value of $112,159.00. Following the completion of the sale, the executive vice president now directly owns 362,909 shares of the company’s stock, valued at approximately $5,352,907.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $14.67, for a total value of $64,548.00. Following the completion of the sale, the chief executive officer now directly owns 731,859 shares of the company’s stock, valued at $10,736,371.53. The disclosure for this sale can be found here. Insiders sold a total of 56,609 shares of company stock valued at $828,405 over the last ninety days. Corporate insiders own 16.20% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
What are top analysts saying about Atara Biotherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Atara Biotherapeutics Inc. and related companies.